Krystal Biotech二季度VYJUVEK收入小幅低于预期且德国定价与KB801时点压制情绪

Earnings Call Insights: Krystal Biotech (KRYS) Q2 2026
Management View
- Krish Krishnan (Founder, Chairman, President & CEO) said the company stayed “focused on execution in Q2,” citing continued growth in U.S. demand and ongoing international launch work, including that Krystal is “advancing pricing and reimbursement discussions in Germany, France, Italy, Spain and the U.K.” while “work[ing] diligently to meet that demand and broaden access for DEB patients around the world.”
- Krishnan highlighted pipeline breadth and timing, saying Krystal has “2 registrational studies underway” (neurotrophic keratitis and ocular lesions in DEB), with repeat-dose studies in cystic fibrosis and Hailey-Hailey disease progressing; “assuming supportive data, we believe both programs have the potential to advance into registrational development in 2027.”
- Laurent Goux (Executive VP & Head of International) described the overseas launch backdrop as “strong and building,” but said reported Europe/Japan revenue was “broadly flat in the quarter, primarily due to a reserve provision related to the ongoing pricing process in Germany,” adding, “This does not change our assessment of the underlying launch trajectory.”
- Christine Wilson (Senior VP & Head of US Commercial) reported, “U.S. net revenue was $91.6 million for the quarter,” and said the company reached “more than 730 U.S. reimbursement approvals for VYJUVEK,” adding, “We have now surpassed our initial penetration target of 60% and have no plans of stopping there.”
- Kathryn Romano (Executive VP & Chief Accounting Officer) said, “Net revenue from global sales of VYJUVEK was $119.2 million for the quarter,” and added, “We continue to expect to incur in the range of $175 million to $195 million in non-GAAP R&D and SG&A expenses for the full year of 2026.”
Outlook
- Romano said expense guidance was unchanged: “We continue to expect to incur in the range of $175 million to $195 million in non-GAAP R&D and SG&A expenses for the full year of 2026.”
- Goux reiterated timing expectations for key European access milestones: “In Germany, Italy and Spain, we continue to expect key outcomes before the end of 2026,” while noting, “In France, formal pricing and reimbursement discussions are expected to progress into 2027.”
- On Germany’s pricing accrual mechanics, Krish Krishnan (Founder, Chairman, President & CEO) said the company was “expecting at this moment to complete negotiations in Q3,” adding that accrual was “completely in Q2 and maybe a partial in Q3” and “hopefully, by the time Q4 comes around, we’ll be back to an actual net revenue number in Germany.”
- On clinical timing, Suma Krishnan (Founder, President of R&D and Director) said KB803’s registrational IOLITE study “was fully enrolled in April” and is “on track for a readout later this year,” while KB801 (NK) enrollment is expected to complete “before year-end” with an “8-week primary endpoint” and “a readout soon thereafter.”
Financial Results
- Romano reported quarterly results including: global VYJUVEK net revenue of $119.2 million; cost of goods sold of $6.4 million; gross margin of 95%; R&D expenses of $14.5 million; G&A expenses of $39.9 million; and net income of $54.8 million, or $1.85 basic EPS and $1.79 diluted EPS.
- Romano said Europe’s quarter-over-quarter dynamics were influenced by Germany pricing accrual: “this quarter also included a full quarter of accrued pricing for Germany… which contributed to reduced quarter-over-quarter net European revenue despite growth in related vial sales.”
- Romano stated balance sheet strength increased again: “now exceeding $1.1 billion in overall cash and investments.”
Q&A
- Jiale Song, Jefferies: asked about Europe demand/compliance and expectations for Hailey-Hailey Phase I data and market opportunity; Executive VP Goux answered, “the demand is strong,” and added that “over 180 patients have been treated in Western Europe and Japan so far,” while Suma Krishnan (Founder, President of R&D and Director) said the company has “over 60 to 70 patients already enrolled” in Hailey-Hailey natural history and expects to “report interim results before year-end,” with a goal to “start registrational trial early next year.”
- Alec Stranahan, BofA Securities: asked about a KB801 complete-closure patient and CF functional metrics; Krish Krishnan (Founder, Chairman, President & CEO) cautioned, “not have the investment community read too much into a single patient data,” and Suma Krishnan said CF repeat-dose follow-up will measure “FEV1 over 6 months” in “approximately 5 patients.”
- Yigal Nochomovitz, Citigroup: pressed for Germany specificity and NK readout timing; Executive VP Goux said, “We don’t provide country-by-country details,” while Krish Krishnan said Germany pricing negotiations were expected to complete in “Q3,” and Suma Krishnan indicated NK data would be “potentially ’27… early ’27 by the time we clean the database and announce data.”
- Ritu Baral, TD Cowen: asked if NK timelines were adjusted for EU sites and about remaining U.S. community opportunity; Suma Krishnan said, “we are not upsizing the study trial,” but are adding EU sites to “do global filing,” while Christine Wilson said, “we continue to believe there’s opportunity in the community setting,” and Krish Krishnan reiterated the diagnosed base as “about 1,200 identified patients,” with future expansion efforts toward “the 3,000 or so… undiagnosed.”
- Lachlan Hanbury-Brown, William Blair: asked about Germany reforms and U.S. PBM dynamics for at-home administration; Krish Krishnan responded, “we’ve had really good access,” and Goux said German negotiations were “very constructive.”
- Debjit Chattopadhyay, Guggenheim: asked about NK commercial opportunity/read-through from ocular DEB and potential salesforce prep; Krish Krishnan called NK “a large and growing market,” while Suma Krishnan said DEB ocular (KB803) and NK (KB801) are “apples and oranges,” and Krish Krishnan said salesforce planning was “a little early.”
- Kalpit Patel, Wolfe Research: asked about ocular DEB geography, NK trial demand, and European sequential sales excluding accrual; Suma Krishnan said ocular DEB is “just focused on the U.S.,” and Krish Krishnan said Europe sales increased sequentially “in the double digits.”
Sentiment Analysis
- Analysts’ tone was slightly negative to neutral around Europe, driven by repeated requests for Germany-specific growth and accrual impacts (including requests for “country-by-country details” and “approximately how much”), while also showing constructive interest in pipeline breadth (NK, CF, Hailey-Hailey, ocular DEB).
- Management’s tone in prepared remarks was positive and execution-focused, including Krish Krishnan’s “very strong financial position” and Goux’s “very encouraged” international momentum, while Q&A responses were more guarded on disclosure (Goux: “We don’t provide country-by-country details”) and more cautionary on single-patient interpretation (Krish Krishnan: “not have the investment community read too much into a single patient data”).
- Versus the prior quarter, Q2 included more back-and-forth on Germany accrual mechanics and a clearer expectation for NK data timing drifting into early 2027, compared with Q1 language that the NK study was “on track for a data readout later this year.”
Quarter-over-quarter Comparison
- Commercial emphasis was consistent, but Q2 discussion centered more on Germany reserve/accrual effects; Goux said Europe/Japan revenue was “broadly flat… due to a reserve provision,” while Q1 highlighted that Europe+Japan “contributed to $28.9 million in net revenue” and estimated “more than 140 DEB patients have been prescribed.”
- U.S. momentum language remained similar (community expansion and approvals), with Q2 reporting “more than 730” approvals versus “over 695” in Q1, and Q2 reiterating penetration beyond “60%.”
- Clinical timelines shifted in tone for NK: Q1 said NK was “on track for a data readout later this year,” while Q2 framed the post-enrollment readout as “soon thereafter,” with Suma Krishnan acknowledging reporting could be “early ’27.”
- Analysts in both quarters focused on Europe access mechanics and the start/stop dynamic in the U.S., with Q2 intensifying follow-ups on Germany-specific revenue normalization and sequential trends.
Risks and Concerns
- Management flagged market-specific launch friction tied to access requirements, including Germany pricing accruals/reserves, France’s hospital-based administration constraint “due to the requirement associated with its GMO classification,” and Japan’s “intensive prescription renewal” burden in year one.
- Management’s mitigation framing centered on execution and conservative accounting: Goux said teams are “navigat[ing] the access and operational dynamics unique to each market,” while Krish Krishnan said the company’s objective is “to be conservative in the accrual and get it over with once the pricing is established in Germany.”
- Clinical disclosure risk surfaced around KB801: Krish Krishnan noted a “legal requirement” drove disclosure of single-patient data and warned against extrapolation to the registrational study.
Final Takeaway
Krystal management framed Q2 around sustained VYJUVEK demand with U.S. net revenue of $91.6 million and ongoing overseas access work that is being temporarily obscured by Germany pricing accruals, while keeping 2026 non-GAAP operating expense guidance unchanged at $175 million to $195 million. The company emphasized multiple near-term clinical catalysts, led by a KB803 readout “later this year” and progressing KB801 enrollment with an expected readout after year-end, alongside repeat-dose CF and Hailey-Hailey interim data “before year-end,” as it positions for multiple registrational initiatives beginning in 2027.
Read the full Earnings Call Transcript